For example, in patients with advanced non-small cell lung cancer (NSCLC), a combination of PD-1 and CTLA-4 inhibitors (nivolumab/ipilimumab) resulted in a higher response rate and better progression-free survival time than those receiving chemotherapy alone.23 This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.